Latest Earnings Results: Q3 '26
Estimated EPS
-$0.50
Reported EPS
-$0.58
Surprise
-15.55%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.58 up 96.78% YoY • As of September 30, 2026, Hemab Therapeutics had $430.2M in cash, cash equivalents, and marketable securities and believes those resources will fund operating expenses and capital expenditure requirements into 2029.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.57 | -- | -- | N/A |
Q3 '26 | -$0.50 | -$0.58 | -15.55% | MISSED |
Q2 '26 | -$0.73 | -$0.80 | -9.22% | MISSED |
Q1 '26 | -$23.25 | -- | -- | N/A |